公开(公告)号：AU2016209056A1

公开(公告)日：2017-07-20

申请号：AU2016209056

申请日：2016-01-25

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  CHEUNG SARAH K C ,  CHUANG PO-KAI ,  HSU TSUI-LING

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

公开(公告)号：AU2015267044A1

公开(公告)日：2016-12-15

申请号：AU2015267044

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HEUY ,  WU CHUNG-YI

IPC: A61K39/395

Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：ES2442024T3

公开(公告)日：2014-02-07

申请号：ES09798721

申请日：2009-07-15

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSENG SUSAN Y

IPC: C40B40/12 ,  C40B50/14

Abstract: Una matriz de carbohidratos inmovilizados en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio polifluorado (de tipo politetrafluoroetileno (PTFE)),comprendiendo la matriz: una pluralidad de carbohidratos inmovilizados en localizaciones específicas en una superficie del sustrato sólidono transparente revestido con aluminio, de modo que: (a) los carbohidratos inmovilizados pueden caracterizarse por espectroscopia de masas (EM) y (b) puede realizarse análisis de reacciones de unión entre los carbohidratos y moléculas que se sospechaque se unen específicamente con los carbohidratos, donde el aluminio se usa para revestir un primer sustrato sólido transparente a un grosor mayor de 100 nm paraconvertir el primer sustrato sólido transparente en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio de tipo PTFE polifluorado y donde la superficie del revestimiento de aluminio en el sustrato sólido se anodiza para formar una capa de óxidode aluminio porosa de un grosor menor de 5 nm.

公开(公告)号：HK1153273A1

公开(公告)日：2012-03-23

申请号：HK11107458

申请日：2011-07-18

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  WANG CHENG-CHI ,  YU ALICE L

IPC: G01N20060101

Abstract: A cancer diagnostic method using a glycan array that contains Gb5 and Globo H, Bb2, Bb3, and/or Bb4.

公开(公告)号：CA3034876C

公开(公告)日：2022-10-04

申请号：CA3034876

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：HK1254775A1

公开(公告)日：2019-07-26

申请号：HK18113821

申请日：2018-10-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P20060101

公开(公告)号：AU2017315677A1

公开(公告)日：2019-04-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2015377230A1

公开(公告)日：2017-07-13

申请号：AU2015377230

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：AU2015305332A1

公开(公告)日：2017-03-09

申请号：AU2015305332

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  LEE HSIN-YU

IPC: C07K14/33 ,  C07K14/34

Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.

公开(公告)号：CA2973886A1

公开(公告)日：2016-08-04

申请号：CA2973886

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/10 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.